This week, we dive into the most significant shift in ASEAN's MedTech regulatory landscape: the rise of reliance pathways. Discover how new pilot programs between Malaysia, Singapore, and Thailand are creating strategic shortcuts for medical device registration, potentially saving companies months of time and significant capital.

We explore a game-changing case where a device approved in one ASEAN nation gains an expedited, abridged review in another. This isn't just theory; it's a new reality that challenges the old model of costly, country-by-country approvals. Learn how this shift is turning single-market approvals into a strategic 'domino effect' for regional access.

Key Questions Answered (本期干货):

1. What is the Malaysia-Singapore regulatory reliance program and how does it work?

2. How can the new Malaysia-Thailand pilot for Class B/C/D devices cut your time-to-market?

3. Which country should you target first to maximize benefits across the region?

4. Are these "shortcuts" a guaranteed approval, or are there hidden pitfalls?

5. What documentation is still required even with an expedited review?

6. How does this trend align with global harmonization efforts by the IMDRF?

7. What does this mean for your company's 2026-2027 ASEAN market entry budget and strategy?

8. How do you choose a local representative who understands these new dynamics?

At Pure Global, we specialize in transforming these complex regulatory shifts into actionable market access strategies. With our deep local expertise and advanced data tools, we help MedTech and IVD companies navigate these new reliance pathways efficiently. Don't just enter a market; leverage it. Contact us at [email protected] or visit https://pureglobal.com to learn more.